View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 19, 2021

Entasis reports positive data from Phase III Acinetobacter drug trial

SUL-DUR met the trial’s primary safety goal, attaining a statistically significant reduction in nephrotoxicity.

Entasis Therapeutics has reported positive topline data from the international Phase III ATTACK clinical trial of sulbactam-durlobactam (SUL-DUR) drug in people with Acinetobacter baumannii-caused infections.

The gram-negative, opportunistic human pathogen Acinetobacter infects critically ill people and occasionally leads to severe pneumonia and infections in the bloodstream.

An intravenous (IV) experimental drug, SUL-DUR combines an IV β-lactam antibiotic, sulbactam, and a new broad-spectrum IV inhibitor of β-lactamase, durlobactam.

Commenced in April 2019, the two-part Phase III trial analysed the safety and efficacy of SUL-DUR versus colistin.

It enrolled 207 subjects at 95 trial centres in 17 nations.

The randomised, comparative Part A segment had subjects with documented Acinetobacter baumannii hospital-acquired bacterial pneumonia (HABP), ventilated pneumonia (VP) ventilator-associated bacterial pneumonia (VABP), or bacteremia.

Part B was the open-labelled segment and enrolled participants with ABC infections who are resistant to or did not respond to therapy with colistin or polymyxin B.

Findings showed that SUL-DUR met the primary goal of 28-day all-cause mortality in subjects with carbapenem-resistant Acinetobacter infections (CRABC) m-MITT population of Part A.

This data signifies the statistical non-inferiority of the treatment against colistin.

Mortality was 19% in the SUL-DUR arm versus 32.3% in subjects who received colistin.

SUL-DUR also met the primary safety goal of the trial attaining a statistically significant decline in nephrotoxicity.

Nearly 61.9% in the SUL-DUR group had a statistically significant difference in clinical cure at test of cure (TOC) versus 40.3% in the colistin group.

Furthermore, the 28-day all-cause death was 17.9% in the Part B segment which is in line with the Part A data.

Overall adverse events (AEs) in the safety population were similar across the treatment arms.

Entasis Therapeutics CEO Manos Perros said: “ATTACK was a landmark clinical trial, the first to successfully evaluate an investigational agent targeting a specific drug-resistant Gram-negative pathogen.

“SUL-DUR is the first investigational drug to demonstrate efficacy in a 28-day all-cause mortality trial focused on carbapenem-resistant Acinetobacter, an Urgentthreat as designated by the CDC.”

The company plans to include this data for new drug applications anticipated to be submitted mid-next year.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU